Abstract
Background
Antimicrobial prophylaxis is considered beneficial for preventing surgical-site infections in clean orthopaedic surgery. However, whether tissue concentrations of cefazolin achieve the minimum inhibitory concentration for the targeted contaminants have yet to be clarified.
Questions/purposes
We asked whether 2 g of cefazolin would enable effective serum and bone concentrations relative to the current minimum inhibitory concentration for cefazolin-resistant coagulase-negative Staphylococci and methicillin-sensitive Staphylococcus aureus.
Patients and Methods
We enrolled 43 patients (THA, n = 16; TKA, n = 27) scheduled for primary THAs and primary TKAs. Subjects were given 2 g of cefazolin intravenously before incision. One blood sample and two bone samples were collected from each subject before tourniquet deflation before any additional dose. All samples were assayed at the same laboratory. Minimum inhibitory concentration values were defined based on nationwide surveys.
Results
Mean (± standard deviation) serum concentration was 170.3 ± 51.3 μg/mL (range, 99.3–370.3 μg/mL). Mean bone concentration was 32.3 ± 15.2 μg/g (range, 11.4–70.0 μg/g) in THA, and 16.0 ± 10.4 μg/g (range, 6.3–46.3 μg/g) in TKA. All serum and bone concentrations exceeded the minimum inhibitory concentration for methicillin-sensitive S. aureus, but some serum levels were marginal and no bone levels exceeded the minimum inhibitory concentration for cefazolin-resistant coagulase-negative Staphylococcus.
Conclusions
Our data suggest intravenous administration of 2 g of cefazolin achieves the minimum inhibitory concentration for methicillin-sensitive S. aureus in serum and bone, but not the minimum inhibitory concentration for cefazolin-resistant coagulase-negative Staphylococcus in bone, resulting in a potential risk of deep surgical site infections in THAs and TKAs.
Similar content being viewed by others
References
Bannister GC, Auchincloss JM, Johnson DP, Newman JH. The timing of tourniquet application in relation to prophylactic antibiotic administration. J Bone Joint Surg Br. 1988;70:322–324.
Bernard L, Sadowski C, Monin D, Stern R, Wyssa B, Rohner P, Lew D, Hoffmeyer P. The value of bacterial culture during clean orthopedic surgery: a prospective study of 1,036 patients. Infect Control Hosp Epidemiol. 2004;25:512–514.
Bratzler DW, Houck PM; Surgical Infection Prevention Guidelines Writers Workgroup; American Academy of Orthopaedic Surgeons; American Association of Critical Care Nurses; American Association of Nurse Anesthetists; American College of Surgeons; American College of Osteopathic Surgeons; American Geriatrics Society; American Society of Anesthesiologists; American Society of Colon and Rectal Surgeons; American Society of Health-System Pharmacists; American Society of PeriAnesthesia Nurses; Ascension Health; Association of periOperative Registered Nurses; Association for Professionals in Infection Control and Epidemiology; Infectious Diseases Society of America; Medical Letter; Premier; Society for Healthcare Epidemiology of America; Society of Thoracic Surgeons; Surgical Infection Society. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004;38:1706–1715.
Chang Y, Shih HN, Chen DW, Lee MS, Ueng SW, Hsieh PH. The concentration of antibiotic in fresh-frozen bone graft. J Bone Joint Surg Br. 2010;92:1471–1474.
Chin NX, Neu NM, Neu HC. Activity of cephalosporins against coagulase-negative staphylococci. Diagn Microbiol Infect Dis. 1990;13:67–69.
Cunha BA, Gossling HR, Pasternak HS, Nightingale CH, Quintiliani R. The penetration characteristics of cefazolin, cephalothin, and cephradine into bone in patients undergoing total hip replacement. J Bone Joint Surg Am. 1977;59:856–859.
Dalstrom DJ, Venkatarayappa I, Manternach AL, Palcic MS, Heyse BA, Prayson MJ. Time-dependent contamination of opened sterile operating-room trays. J Bone Joint Surg Am. 2008;90:1022–1025.
Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004;350:1422–1429.
Fletcher N, Sofianos D, Berkes MB, Obremskey WT. Prevention of perioperative infection. J Bone Joint Surg Am. 2007;89:1605–1618.
Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery. 1989;106:750–756; discussion 756–757.
Friedman RJ, Friedrich LV, White RL, Kays MB, Brundage DM, Graham J. Antibiotic prophylaxis and tourniquet inflation in total knee arthroplasty. Clin Orthop Relat Res. 1990;260:17–23.
Friedrich LV, White RL, Brundage DM, Kays MB, Friedman RJ. The effect of tourniquet inflation on cefazolin tissue penetration during total knee arthroplasty. Pharmacotherapy. 1990;10:373–377.
Fujimura T, Yoshida I, Itoh Y, Tachibana M, Kaku M, Kanemitsu K, Takahashi C, Shiotani J, Ono Y, Baba H, Matsuo S, Asari S, Matsuoka K, Kusano N, Nose M, Saikawa T, Hiramatsu K, Kohno S, Hirakata Y, Yamane N, Nakasone I, Yamano Y. [Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2004][in Japanese]. Jpn J Chemother. 2008;56:543–561.
Garza-Gonzalez E, Morfin-Otero R, Llaca-Diaz JM, Rodriguez-Noriega E. Staphylococcal cassette chromosome mec (SCC mec) in methicillin-resistant coagulase-negative staphylococci: a review and the experience in a tertiary-care setting. Epidemiol Infect. 2010;138:645–654.
Irie S, Terakawa M, Ishibashi K, Tabata K, Suzuki S, Yokota Y. [Pharmacokinetic study of a parenteral cephalosporin, cefazolin in healthy volunteers given Cefamezin® -infusion 1-g kit][in Japanese]. Kagakuryouhou no Ryouiki. 1999;15:766–774.
Johnson DP. Antibiotic prophylaxis with cefuroxime in arthroplasty of the knee. J Bone Joint Surg Br 1987;69:787–789.
Kimura Y, Nagano K, Higashiyama I, Jinushi Y, Sasaki S, Yoshida I. [Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial agents -No.1 against Gram-positive cocci isolated in 1994][in Japanese]. Jpn J Chemother. 1996;44:595–609.
Kimura Y, Yoshida I, Higashiyama I, Nagano K, Sasaki S. [Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial agents -No.1 against Gram-positive cocci isolated in 1996][in Japanese]. Jpn J Chemother. 1998;46:324–342.
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20:250–278; quiz 279–280.
Moran E, Masters S, Berendt AR, McLardy-Smith P, Byren I, Atkins BL. Guiding empirical antibiotic therapy in orthopaedics: the microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Infect. 2007;55:1–7.
Nickinson RS, Board TN, Gambhir AK, Porter ML, Kay PR. The microbiology of the infected knee arthroplasty. Int Orthop. 2010;34:505–510.
Oliveira AD, d’Azevedo PA, de Sousa LB, Viana-Niero C, Francisco W, Lottenberg C, Martino MD, Hofling-Lima AL. Laboratory detection methods for methicillin resistance in coagulase negative Staphylococcus isolated from ophthalmic infections. Arq Bras Oftalmol. 2007;70:667–675.
Osmon DR. Antimicrobial resistance: guidelines for the practicing orthopaedic surgeon. Instr Course Lect. 2002;51:527–537.
Ostrander RV, Botte MJ, Brage ME. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am. 2005;87:980–985.
Prokuski L. Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg. 2008;16:283–293.
Quintiliani R, Nightingale C. Principles of antibiotic usage. Clin Orthop Relat Res. 1984;190:31–35.
Raad I, Alrahwan A, Rolston K. Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin Infect Dis. 1998;26:1182–1187.
Rafiq I, Gambhir AK, Wroblewski BM, Kay PR. The microbiology of infected hip arthroplasty. Int Orthop. 2006;30:532–535.
Saegeman V, Lismont D, Verduyckt B, Ectors N, Stuyck J, Verhaegen J. Antimicrobial susceptibility of coagulase-negative staphylococci on tissue allografts and isolates from orthopedic patients. J Orthop Res. 2007;25:501–507.
Savitz SI, Savitz MH, Goldstein HB, Mouracade CT, Malangone S. Topical irrigation with polymyxin and bacitracin for spinal surgery. Surg Neurol. 1998;50:208–212.
Schurman DJ, Hirshman HP, Kajiyama G, Moser K, Burton DS. Cefazolin concentrations in bone and synovial fluid. J Bone Joint Surg Am. 1978;60:359–362.
Sørensen TS, Colding H, Schroeder E, Rosdahl VT. The penetration of cefazolin, erythromycin and methicillin into human bone tissue. Acta Orthop Scand. 1978;49:549–553.
Whitehouse JD, Friedman ND, Kirkland KB, Richardson WJ, Sexton DJ. The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol. 2002;23:183–189.
Wikler MA, Cockerill FR, Craig WA, Dudley MN, Eliopoulos GM, Hecht DW, Hindler JF, Low DE, Sheehan DJ, Tenover FC, Turnidge JD, Weinstein MP, Zimmer BL, Ferraro MJ, Swenson JM. Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
Williams DN, Gustilo RB, Beverly R, Kind AC. Bone and serum concentrations of five cephalosporin drugs: relevance to prophylaxis and treatment in orthopedic surgery. Clin Orthop Relat Res. 1983;179:253–265.
World Health Organization. WHO Guidelines for Safe Surgery: 2009: Safe Surgery Saves Lives. Available at: http://whqlibdoc.who.int/publications/2009/9789241598552_eng.pdf. Accessed November 18, 2010.
Yamada K, Okazaki H, Iga T, Nagai I, Tatsumi T, Touhara C, Sato W, Hasegawa J, Tanaka S, Matsudaira K, Nakamura K. [The surgical site is contaminated even in the clean orthopaedic surgery][in Japanese]. Nippon Seikeigeka Gakkai Zasshi. 2010;84:S707.
Yoshida I, Kimura Y, Higashiyama I, Sugimori G, Yamano Y. [Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial agents: antimicrobial activity against gram-positive cocci and anaerobic bacteria isolated in 2000][in Japanese]. Jpn J Chemother. 2003;51:179–208.
Acknowledgments
We thank Satoshi Kishino for invaluable support for analyzing the samples, Dr. Toshikazu Tsuboi, Dr. Yasuo Ohori, Dr. Toru Iga, Dr. Ichiro Nagai, Dr. Tetsushi Tatsumi, and Dr. Chiemi Touhara for recruiting the patients, and Dr. Ko Matsudaira, Dr. Hiroyuki Oka, and Hiroshi Ohtsu for statistical support during the course of this study.
Author information
Authors and Affiliations
Corresponding author
Additional information
Each author certifies that he or she has no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article.
All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research editors and board members are on file with the publication and can be viewed on request.
Each author certifies that his or her institution approved the human protocol for this investigation, that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained.
This work was performed at Tokyo Metropolitan Tama Medical Center (Tokyo, Japan) and Tama-Hokubu Medical Center (Tokyo, Japan).
About this article
Cite this article
Yamada, K., Matsumoto, K., Tokimura, F. et al. Are Bone and Serum Cefazolin Concentrations Adequate for Antimicrobial Prophylaxis?. Clin Orthop Relat Res 469, 3486–3494 (2011). https://doi.org/10.1007/s11999-011-2111-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11999-011-2111-8